Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA.
Department of Oral and Maxillofacial-Head Neck Oncology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
J Cell Biochem. 2022 Feb;123(2):215-230. doi: 10.1002/jcb.30188. Epub 2021 Dec 13.
Sharing a common DNA binding motif called T-box, transcription factor T-box gene family controls embryonic development and is also involved in cancer progression and metastasis. Cancer metastasis shows therapy resistance and involves complex processes. Among them, epithelial-mesenchymal transition (EMT) triggers cancer cell invasiveness and the acquisition of stemness of cancer cells, called cancer stem cells (CSCs). CSCs are a small fraction of tumor bulk and are capable of self-renewal and tumorsphere formation. Recent progress has highlighted the critical roles of T-box genes in cancer progression, EMT, and CSC function, and such regulatory functions of T-box genes have emerged as potential therapeutic candidates for cancer. Herein we summarize the current understanding of the regulatory mechanisms of T-box genes in cancer, EMT, and CSCs, and discuss the implications of targeting T-box genes as anticancer therapeutics.
T 盒转录因子家族通过共享一个称为 T 盒的共同 DNA 结合基序,控制胚胎发育,并且还参与癌症的进展和转移。癌症转移表现出治疗耐药性,并涉及复杂的过程。其中,上皮-间充质转化(EMT)引发癌细胞的侵袭和癌细胞获得干性,称为癌症干细胞(CSCs)。CSCs 是肿瘤块的一小部分,能够自我更新和形成肿瘤球。最近的进展强调了 T 盒基因在癌症进展、EMT 和 CSC 功能中的关键作用,并且 T 盒基因的这种调节功能已成为癌症治疗的潜在候选药物。本文总结了 T 盒基因在癌症、EMT 和 CSCs 中的调控机制的最新认识,并讨论了作为抗癌治疗的靶向 T 盒基因的意义。